Trials / Completed
CompletedNCT04484779
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
User Experience and Daily Use Patterns With the Integrated Insulin Management (IIM) System
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes. The IIM system is comprised of an insulin injection pen with a data transmission module and blood glucose meter which are connected to a mobile phone application. The application will be used to record and track diabetes-data related information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | IIM System | IIM System |
| DRUG | Insulin Lispro and/or Insulin Glargine | Administered subcutaneously (SC) |
Timeline
- Start date
- 2020-07-14
- Primary completion
- 2020-12-22
- Completion
- 2020-12-22
- First posted
- 2020-07-24
- Last updated
- 2021-01-07
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04484779. Inclusion in this directory is not an endorsement.